Citadel Advisors
CGTX icon

Citadel Advisors’s Cognition Therapeutics CGTX Stock Holding History

Citadel Advisors’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.7K Sell
25,905
-135,296
-84% -$157K ﹤0.01% 12674
2025
Q4 		$218K Buy
+161,201
New +$262K ﹤0.01% 10861
2024
Q3 		– Sell
-26,950
Closed -$44.7K – 14314
2024
Q2 		$44.7K Buy
+26,950
New +$53.7K ﹤0.01% 11892
2022
Q2 		– Sell
-10,504
Closed -$28K – 12968
2022
Q1 		$28K Buy
+10,504
New +$40.5K ﹤0.01% 13127

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Citadel Advisors's CGTX Position: Q1 2026 in Review

Citadel Advisors reduced its Cognition Therapeutics (CGTX) stake by 84% in Q1 2026, selling an estimated $157K and leaving 25,905 shares worth $19.7K. The position accounts for ﹤0.01% of the portfolio, ranked #12674.

Citadel Advisors first reported a position in CGTX in Q1 2022 and has held it in 4 quarters since. The position peaked at $218K in Q4 2025. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • Citadel Advisors held 25,905 shares of Cognition Therapeutics worth $19.7K as of Q1 2026.
  • Citadel Advisors sold 135,296 Cognition Therapeutics shares in Q1 2026, an estimated $157K.
  • Cognition Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12674 holding.
  • Citadel Advisors first reported a position in Cognition Therapeutics in Q1 2022 and has held it in 4 quarters since.
  • Citadel Advisors's Cognition Therapeutics position peaked at $218K in Q4 2025.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.